Antibodies

Avoidance of cephalosporins and penicillin with beta-lactamase inhibitors during anti-TNF therapy reduced the risk for anti-drug antibodies among patients with inflammatory bowel disease, according to research published in Gut.

Among young patients with inflammatory bowel disease, most whom were positive for SARs-CoV-2, had a non-neutralizing antibody, according to data presented at Digestive Disease Week.

Serological responses from patients with inflammatory bowel disease on biologic therapies had 100% seropositivity after two doses of the COVID-19 mRNA vaccinations, according to a study published in Gastroenterology.

Researchers reported that African American and Hispanic health care workers were more likely to test positive for SARS-CoV-2 antibodies than non-Hispanic white health care workers.

Patients with COVID-19 antibodies appear to be protected against reinfection for at least a few months, according to research published JAMA Internal Medicine.

Although the risk for vertical transmission of COVID-19 appears rare, a lower-than-expected rate of transplacental transfer of antibodies suggests children born to infected mothers may be at risk for infection, according to a study published in JAMA Network Open.

Patients with uncontrolled gout treated with pegloticase and mycophenolate mofetil exhibited reduced probability of developing antibodies to pegloticase and improved response rates at 12 weeks, according to data presented at ACR 2020.

Antibodies in adults with diabetes hospitalized with COVID-19 in Italy had a similar positive response to the SARS-CoV-2 spike protein as those without diabetes, according to findings published in Diabetologia.

Researchers detected anti-SARS-CoV-2 IgG antibodies in the blood samples of some pediatric patients prior to viral clearance, according to a study published in The Journal of Pediatrics.

Research and data on potential treatment modalities continue to emerge at a rapid pace. This episode explores the IDSA and NIH guidelines for the treatment and management of COVID-19, as well as available evidence on antivirals, glucocorticoids and antibodies.